Press releases

31 March, 2015

Regulatory

NeuroVive Pharmaceutical AB (publ) – amendment number of shares and votes

Pursuant to chapter 4, § 9 of the Swedish Financial Instruments Trading Act (1991:980), the company is hereby reporting that as a result of new share issue conducted by NeuroVive Pharmaceutical AB (pu ...

30 March, 2015

Regulatory

NeuroVive Pharmaceutical AB (publ): report from AGM

NeuroVive Pharmaceutical AB (publ) held its Annual General Meeting (AGM) yesterday, 30 March 2015. A summary of the resolutions follows. All resolutions were passed with the required majority.

18 March, 2015

Regulatory

NeuroVive Pharmaceutical publishes English version of annual report for 2014

NeuroVive Pharmaceutical AB (publ) today announced that the English version of the annual report for 2014 is now available on the company's website www.neurovive.com.The annual report can also be acce ...

25 February, 2015

Regulatory

Notice of Annual General Meeting of NeuroVive Pharmaceutical AB (publ)

The shareholders of NeuroVive Pharmaceutical AB (publ), corporate identity number 556595-6538, are hereby convened to the Annual General Meeting, held at 4 p.m. on Monday, 30 March 2015 at Medicon Vil ...

20 February, 2015

Regulatory

NeuroVive completes a directed share issue of SEK 65 million for continued expansion

NeuroVive Pharmaceutical AB (publ) (”NeuroVive” or the “Company”, OMX:NVP) today announces that the Company has completed a directed share issue of 1.3 million new shares, whic ...

18 February, 2015

Regulatory

NeuroVive: Year-End Report 1 Jan. 2014 till 31 Dec. 2014

Fourth Quarter (1 Oct. 2014 - 31 Dec. 2014) · Net revenues were SEK 0 (0) and other operating income was SEK 8,000 (12,000). · Loss before tax was SEK -17,346,000 (9,169,000). · Earnings per share* we ...

11 February, 2015

Regulatory

New subsidiary secures funding of just over USD 3 m ahead of potential IPO in Taiwan

NeuroVive has established a subsidiary in Taiwan, NeuroVive Pharmaceutical Asia, Inc., which has secured initial funding totaling USD 3,255 m. The funding is sourced from Taiwanese investors, collabor ...

5 February, 2015

Regulatory

OnCore Biopharma and Tekmira Pharmaceuticals files for merger – releases further details about license agreement with NeuroVive

NeuroVive Pharmaceutial AB, a leading mitochondrial medicine company, is able to present further details regarding the previously communicated exclusive, worldwide licensing agreement with OnCore Biop ...

19 January, 2015

Regulatory

Merger between OnCore and Tekmira includes development of NVP018 for the treatment of Hepatitis B

US biotechnology company OnCore Biopharma, Inc. (OnCore), which has licensed NeuroVive's drug candidate NVP018 for the treatment of chronic Hepatitis B virus infection (HBV), has agreed to merge with ...

12 January, 2015

Regulatory

Annual General Meeting brought forward to March 30 2015

The Board of NeuroVive Pharmaceutical AB (publ) has decided to bring forward the Annual General Meeting 2015 to Monday 30 March, 2015, at 4 p.m. at Medicon Village, Scheelevägen 2, in Lund, Sweden to ...